Regulation of Cell Death in HIV Reservoirs
- Institution
- METHODIST HOSPITAL RESEARCH INSTITUTE, TX
- Principal investigator
- Jin Wang
- Funding
- $576K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
ABSTRACT: The combinational antiretroviral therapy is effective in suppressing HIV-1 replication. However, latent HIV reservoirs cannot be cleared by such antiretroviral therapy, as viral rebound develops rapidly after the treatment is interrupted in people living with HIV. The shock-and-kill approach to eliminate HIV-1 reservoirs is to induce viral reactivation using latency reversal agents and trigger cell death through virus-mediated cytopathic effects or immune-mediated clearance. However, shock-and-kill by latency reversal agents has not been shown to successfully reduce the viral reservoirs in HIV-1 patients. It has been reported that latency reversal agents can up-regulate pro-survival autophagy and anti-apoptotic molecules that counteract cell death signaling. Inhibition of these pro-survival mechanisms can promote the killing of HIV-1-infected cells, and facilitate the killing of HIV-1 reservoir cells during vial re-activation. Experiments are proposed to test hypothesis that cellular mechanisms that maintain the long-term persistence of HIV-1 reservoirs are important for protecting the reservoir cells against cell death, and targeting these cellular mechanisms can sensitize HIV-1 reservoirs to cell death during viral reactivation: 1) To determine the mechanisms for the specific induction of cell death in HIV-1 reservoirs in response to viral reactivation. The mechanisms for the induction of apoptosis and alternative cell death pathways in latent HIV-infected T cells by latency reversal agents will be tested; 2) To delineate the mechanisms that confer the resistance to cell death in HIV-1 reservoirs upon viral reactivation; and 3) To test whether targeting pro-survival mechanisms sensitizes HIV-1 reservoirs cells to cell death during viral re-activation. The studies will reveal novel molecular pathways that could be targeted to sensitize HIV-1 reservoirs to cell death, and facilitate the development of an effective approach to clear HIV-1 reservoirs.
LOADING MOONBASE SCORE
Questions for METHODIST HOSPITAL RESEARCH INSTITUTE
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Baylor College of MedicineNot yet scored
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
Jin Wang · $628K · 2022–2027
- NIH · Baylor College of MedicineNot yet scored
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
Jin Wang · $13K · 2022–2025
- NIH · Methodist Hospital Research InstituteNot yet scored
Targeting the HIV-1 Reservoir in Myeloid Cells
Jin Wang · $484K · 2021–2026